Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics develops and commercializes medicines for children and adults with rare disorders, with a life-science business focused on clinically differentiated therapies in areas including neurology and metabolism. Company news commonly covers product revenue, commercial launch activity, financial guidance, investor presentations, and updates from its rare-disease development portfolio.
Recurring developments include Sephience™ (sepiapterin) launch and revenue updates, clinical and regulatory disclosures involving votoplam, vatiquinone and Translarna™ (ataluren), and partnership-related program responsibilities. PTC also reports governance changes and Nasdaq inducement equity grants tied to employee compensation.
PTC Therapeutics (NASDAQ: PTCT) approved equity inducement awards for 18 new employees on June 11, 2026, under Nasdaq Listing Rule 5635(c)(4). These include non-statutory stock options for 10,050 shares and 11,870 RSUs, each RSU representing one common share upon vesting.
The stock options have a $74.71 exercise price, a 10-year term, and vest over four years: 25% after one year, then 6.25% quarterly. RSUs vest over four years in 25% annual installments, all subject to continued employment.
PTC Therapeutics (NASDAQ: PTCT) priced a private offering of $500 million 0% Convertible Senior Notes due 2031, with an option for an additional $50 million. The notes carry no cash interest, mature June 15, 2031, and are senior unsecured.
According to PTC Therapeutics, net proceeds of about $486.8 million will primarily refinance its 1.5% Convertible Senior Notes due 2026, including a concurrent cash repurchase of $222 million principal for a total cost of approximately $328.8 million. The initial conversion price is $107.48, a 40% premium to the June 15, 2026 close.
PTC Therapeutics (NASDAQ: PTCT) plans a private offering of $500 million Convertible Senior Notes due 2031, with an option for an additional $50 million, to qualified institutional buyers under Rule 144A.
According to PTC, net proceeds will primarily refinance its 1.5% Convertible Senior Notes due 2026 and fund approximately $50 million of common stock repurchases.
PTC Therapeutics (NASDAQ: PTCT) reported Q1 2026 total revenue of $273M, including $226M product revenue, and raised full‑year product revenue guidance to $750–$850M with total revenue guidance of $1.08–$1.18B. Sephience revenue was $124.6M (36% QoQ). Q1 GAAP R&D was $100.9M; GAAP SG&A was $86.2M. Net loss was $2.8M. Cash and marketable securities were $1.892B at March 31, 2026. Clinical updates include positive 24‑month PIVOT‑HD topline results for votoplam and plans to start an open‑label vatiquinone registration study in Q3 2026.
PTC Therapeutics (NASDAQ: PTCT) announced executive presentations at three investor conferences in May–June 2026. Scheduled appearances: Bank of America Health Care Conference on May 12, RBC Capital Markets Global Healthcare on May 20, and Goldman Sachs Global Healthcare Conference on June 9.
Each presentation will be webcast live and archived for 30 days on PTC Therapeutics' investor Events and Presentations page.
PTC Therapeutics (NASDAQ: PTCT) reported positive topline results from the 24-month interim analysis of the PIVOT-HD extension study of votoplam in Huntington's disease on April 28, 2026. Stage 2 participants showed dose-dependent slowing on the cUHDRS: 52% slowing at 10 mg and 28% at 5 mg versus a propensity-weighted natural history cohort.
Mean NfL remained below baseline at 24 months for both doses; safety at Month 24 was consistent with prior data. Novartis has initiated the global Phase 3 INVEST-HD study (≈770 participants, 3:2 randomization to 10 mg or placebo).
PTC Therapeutics (NASDAQ: PTCT) will report results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam on April 28, 2026.
The company will host a webcast and conference call today at 4:30 p.m. ET. Novartis said the long-term data support its now-initiated Phase 3 INVEST-HD study; Novartis and PTC will assess next steps, including possible actions with the FDA.
Live access and a 30-day replay are available on the Investors & Events page; phone participation requires advance registration.
PTC Therapeutics (NASDAQ: PTCT) will report first quarter 2026 financial results on Thursday, May 7, 2026 at 4:30 p.m. ET via a live webcast and conference call. The company will provide a business update and outlook during the event.
A replay will be available on the company's Investors "Events & Presentations" page for 30 days; phone participation requires advance registration for dial-in details.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved April 13, 2026 for a new non-executive employee under Nasdaq Listing Rule 5635(c)(4).
The company granted non-statutory stock options to purchase 1,155 shares and 925 RSUs. Options have a $70.42 exercise price, 10-year term, and four-year vesting schedules; RSUs vest over four years.
PTC Therapeutics (NASDAQ: PTCT) appointed Jessica Chutter to its Board of Directors on March 25, 2026. Ms. Chutter recently retired as Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley after a 40+ year career. She was involved in approximately $80 billion of capital raising and $85 billion of strategic transactions. Management said Ms. Chutter advised PTC previously and will help guide the company’s next stage of growth.